Alkermes launches 180-patient Phase 2 ALKS 7290 trial testing orexin activation in major depression
Alkermes starts a 180-patient Phase 2 ALKS 7290 depression trial, testing orexin activation alongside antidepressants and assessing safety.
Pharma & Biotech